The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of NK012, a polymeric micelle formulation of SN-38, in colorectal cancer patients who had received prior oxaliplatin-based regimen.
 
Akihito Tsuji
Honoraria - Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical
 
Tetsuya Hamaguchi
Speakers' Bureau - Chugai Pharma; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Lilly; NanoCarrier; Sanofi; Sumitomo Group; Teijin Pharma
 
Kensei Yamaguchi
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Merck Serono; Takeda
Research Funding - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck Serono; Quintiles; Taiho Pharmaceutical; Yakult Honsha
 
Koji Takeda
Research Funding - Nippon Kayaku
 
Hiroyuki Uetake
No Relationships to Disclose
 
Taito Esaki
No Relationships to Disclose
 
Kenji Amagai
No Relationships to Disclose
 
Naotoshi Sugimoto
Research Funding - Avantis Medical Systems; Daiichi Sankyo; Lilly; Taivex Therapeutics
 
Hideo Baba
Research Funding - Nippon Kayaku
 
Masami Kimura
No Relationships to Disclose
 
Yasuhiro Matsumura
Research Funding - Nippon Kayaku
 
Yoshihiro Nambu
Employment - Nippon Kayaku
Leadership - Nippon Kayaku
Stock and Other Ownership Interests - Nippon Kayaku